Enterprise Value

38.66B

Cash

1.074B

Avg Qtr Burn

N/A

Short % of Float

2.17%

Insider Ownership

0.16%

Institutional Own.

93.32%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
QALSODY™ BIIB067 (tofersen) Details
Amyotrophic lateral sclerosis

Approved

Update

Approved

Quarterly sales

Approved

Quarterly sales

TOFIDENCE (BIIB800) (tocilizumab) Details
Polyarticular juvenile idiopathic arthritis, Rheumatoid arthritis

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

BLA

Acceptance for review

BLA

Acceptance for review

Dapirolizumab pegol Details
Systemic lupus erythematosus

Phase 3

Data readout

BIIB080 (tau ASO) Details
Alzheimer's disease

Phase 2

Data readout

ATXN2 ASO (BIIB105) Details
Amyotrophic lateral sclerosis

Phase 1/2

Data readout

IONS582 /BIIB121 Details
Angelman Syndrome

Phase 1b

Data readout

BIIB113 Details
Alzheimer's disease

Phase 1

Update

BIIB093 (IV glibenclamide) Details
Acute myocardial infarction

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued